Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Sell
50
RDY Quote, Financials, Valuation and Earnings
Last price:
$15.42
Seasonality move
:
1.57%
Day range:
$15.37 - $15.77
52-week range:
$13.43 - $16.89
Dividend yield:
0.6%
P/E ratio:
33.88x
P/S ratio:
3.76x
P/B ratio:
3.61x
Volume:
1.3M
Avg. volume:
1.6M
1-year change:
10.41%
Market cap:
$13.2B
Revenue:
$3.4B
EPS (TTM):
$0.47
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RDY
Dr Reddy's Laboratories
|
$949.3M | $0.19 | 12.06% | -3.36% | -- |
|
CCM
Concord Medical Services Holdings
|
-- | -- | -- | -- | -- |
|
INFY
Infosys
|
$4.8B | $0.19 | 3.73% | 6.53% | $23.49 |
|
SSII
SS Innovations International
|
-- | -- | -- | -- | -- |
|
YI
111
|
$546.5M | -- | -3.55% | -- | -- |
|
ZLAB
Zai Lab
|
$108.9M | -$0.70 | 65.01% | -27.07% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RDY
Dr Reddy's Laboratories
|
$15.81 | -- | $13.2B | 33.88x | $0.10 | 0.6% | 3.76x |
|
CCM
Concord Medical Services Holdings
|
$4.62 | -- | $20.1M | -- | $0.00 | 0% | 0.31x |
|
INFY
Infosys
|
$22.78 | $23.49 | $94.4B | 29.21x | $0.25 | 2.56% | 4.98x |
|
SSII
SS Innovations International
|
$8.5000 | -- | $458M | -- | $0.00 | 0% | -- |
|
YI
111
|
$0.54 | -- | $46.3M | -- | $0.00 | 0% | 0.02x |
|
ZLAB
Zai Lab
|
$24.30 | -- | $2.6B | -- | $0.00 | 0% | 6.66x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RDY
Dr Reddy's Laboratories
|
12.55% | -0.370 | 3.94% | 1.28x |
|
CCM
Concord Medical Services Holdings
|
273.84% | -5.586 | 77.28% | 0.19x |
|
INFY
Infosys
|
-- | 0.770 | -- | 1.82x |
|
SSII
SS Innovations International
|
-- | -0.161 | -- | -- |
|
YI
111
|
-36.55% | 2.060 | 12.11% | 0.41x |
|
ZLAB
Zai Lab
|
14.47% | -0.405 | 4.76% | 2.39x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RDY
Dr Reddy's Laboratories
|
$570.2M | $215.4M | 18.67% | 19.35% | 24.86% | $16.7M |
|
CCM
Concord Medical Services Holdings
|
-- | -- | -7.49% | -19.78% | -- | -- |
|
INFY
Infosys
|
$1.5B | $1B | 31.76% | 31.76% | 21.11% | -- |
|
SSII
SS Innovations International
|
-- | -- | -- | -- | -- | -- |
|
YI
111
|
$29.4M | $331.2K | -47.45% | -89.07% | 0.12% | $15.5M |
|
ZLAB
Zai Lab
|
$65.3M | -$64M | -33.5% | -35.53% | -40.02% | -$56.7M |
Dr Reddy's Laboratories vs. Competitors
-
Which has Higher Returns RDY or CCM?
Concord Medical Services Holdings has a net margin of 15.66% compared to Dr Reddy's Laboratories's net margin of --. Dr Reddy's Laboratories's return on equity of 19.35% beat Concord Medical Services Holdings's return on equity of -19.78%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr Reddy's Laboratories59.59% $0.04 $4.2B CCMConcord Medical Services Holdings-- -- $727.8M -
What do Analysts Say About RDY or CCM?
Dr Reddy's Laboratories has a consensus price target of --, signalling downside risk potential of -1.96%. On the other hand Concord Medical Services Holdings has an analysts' consensus of -- which suggests that it could grow by 159.74%. Given that Concord Medical Services Holdings has higher upside potential than Dr Reddy's Laboratories, analysts believe Concord Medical Services Holdings is more attractive than Dr Reddy's Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings RDYDr Reddy's Laboratories0 0 0 CCMConcord Medical Services Holdings0 0 0 -
Is RDY or CCM More Risky?
Dr Reddy's Laboratories has a beta of 0.508, which suggesting that the stock is 49.207% less volatile than S&P 500. In comparison Concord Medical Services Holdings has a beta of -0.373, suggesting its less volatile than the S&P 500 by 137.27%.
-
Which is a Better Dividend Stock RDY or CCM?
Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.6%. Concord Medical Services Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.94% of its earnings as a dividend. Concord Medical Services Holdings pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or CCM?
Dr Reddy's Laboratories quarterly revenues are $956.9M, which are larger than Concord Medical Services Holdings quarterly revenues of --. Dr Reddy's Laboratories's net income of $149.8M is higher than Concord Medical Services Holdings's net income of --. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 33.88x while Concord Medical Services Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.76x versus 0.31x for Concord Medical Services Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr Reddy's Laboratories3.76x 33.88x $956.9M $149.8M CCMConcord Medical Services Holdings0.31x -- -- --
-
Which has Higher Returns RDY or INFY?
Infosys has a net margin of 15.66% compared to Dr Reddy's Laboratories's net margin of 15.88%. Dr Reddy's Laboratories's return on equity of 19.35% beat Infosys's return on equity of 31.76%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr Reddy's Laboratories59.59% $0.04 $4.2B INFYInfosys30.53% $0.19 $10.8B -
What do Analysts Say About RDY or INFY?
Dr Reddy's Laboratories has a consensus price target of --, signalling downside risk potential of -1.96%. On the other hand Infosys has an analysts' consensus of $23.49 which suggests that it could grow by 3.12%. Given that Infosys has higher upside potential than Dr Reddy's Laboratories, analysts believe Infosys is more attractive than Dr Reddy's Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings RDYDr Reddy's Laboratories0 0 0 INFYInfosys5 5 1 -
Is RDY or INFY More Risky?
Dr Reddy's Laboratories has a beta of 0.508, which suggesting that the stock is 49.207% less volatile than S&P 500. In comparison Infosys has a beta of 1.001, suggesting its more volatile than the S&P 500 by 0.07299999999999%.
-
Which is a Better Dividend Stock RDY or INFY?
Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.6%. Infosys offers a yield of 2.56% to investors and pays a quarterly dividend of $0.25 per share. Dr Reddy's Laboratories pays 11.94% of its earnings as a dividend. Infosys pays out 56.11% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or INFY?
Dr Reddy's Laboratories quarterly revenues are $956.9M, which are smaller than Infosys quarterly revenues of $4.9B. Dr Reddy's Laboratories's net income of $149.8M is lower than Infosys's net income of $777M. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 33.88x while Infosys's PE ratio is 29.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.76x versus 4.98x for Infosys. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr Reddy's Laboratories3.76x 33.88x $956.9M $149.8M INFYInfosys4.98x 29.21x $4.9B $777M
-
Which has Higher Returns RDY or SSII?
SS Innovations International has a net margin of 15.66% compared to Dr Reddy's Laboratories's net margin of --. Dr Reddy's Laboratories's return on equity of 19.35% beat SS Innovations International's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RDYDr Reddy's Laboratories59.59% $0.04 $4.2B SSIISS Innovations International-- -- -- -
What do Analysts Say About RDY or SSII?
Dr Reddy's Laboratories has a consensus price target of --, signalling downside risk potential of -1.96%. On the other hand SS Innovations International has an analysts' consensus of -- which suggests that it could fall by --. Given that Dr Reddy's Laboratories has higher upside potential than SS Innovations International, analysts believe Dr Reddy's Laboratories is more attractive than SS Innovations International.
Company Buy Ratings Hold Ratings Sell Ratings RDYDr Reddy's Laboratories0 0 0 SSIISS Innovations International0 0 0 -
Is RDY or SSII More Risky?
Dr Reddy's Laboratories has a beta of 0.508, which suggesting that the stock is 49.207% less volatile than S&P 500. In comparison SS Innovations International has a beta of -53.641, suggesting its less volatile than the S&P 500 by 5464.148%.
-
Which is a Better Dividend Stock RDY or SSII?
Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.6%. SS Innovations International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.94% of its earnings as a dividend. SS Innovations International pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or SSII?
Dr Reddy's Laboratories quarterly revenues are $956.9M, which are larger than SS Innovations International quarterly revenues of --. Dr Reddy's Laboratories's net income of $149.8M is higher than SS Innovations International's net income of --. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 33.88x while SS Innovations International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.76x versus -- for SS Innovations International. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr Reddy's Laboratories3.76x 33.88x $956.9M $149.8M SSIISS Innovations International-- -- -- --
-
Which has Higher Returns RDY or YI?
111 has a net margin of 15.66% compared to Dr Reddy's Laboratories's net margin of -0.48%. Dr Reddy's Laboratories's return on equity of 19.35% beat 111's return on equity of -89.07%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr Reddy's Laboratories59.59% $0.04 $4.2B YI1115.85% -$0.03 $67.9M -
What do Analysts Say About RDY or YI?
Dr Reddy's Laboratories has a consensus price target of --, signalling downside risk potential of -1.96%. On the other hand 111 has an analysts' consensus of -- which suggests that it could grow by 1011.87%. Given that 111 has higher upside potential than Dr Reddy's Laboratories, analysts believe 111 is more attractive than Dr Reddy's Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings RDYDr Reddy's Laboratories0 0 0 YI1110 0 0 -
Is RDY or YI More Risky?
Dr Reddy's Laboratories has a beta of 0.508, which suggesting that the stock is 49.207% less volatile than S&P 500. In comparison 111 has a beta of 0.428, suggesting its less volatile than the S&P 500 by 57.162%.
-
Which is a Better Dividend Stock RDY or YI?
Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.6%. 111 offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.94% of its earnings as a dividend. 111 pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or YI?
Dr Reddy's Laboratories quarterly revenues are $956.9M, which are larger than 111 quarterly revenues of $502.9M. Dr Reddy's Laboratories's net income of $149.8M is higher than 111's net income of -$2.4M. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 33.88x while 111's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.76x versus 0.02x for 111. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr Reddy's Laboratories3.76x 33.88x $956.9M $149.8M YI1110.02x -- $502.9M -$2.4M
-
Which has Higher Returns RDY or ZLAB?
Zai Lab has a net margin of 15.66% compared to Dr Reddy's Laboratories's net margin of -40.75%. Dr Reddy's Laboratories's return on equity of 19.35% beat Zai Lab's return on equity of -35.53%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr Reddy's Laboratories59.59% $0.04 $4.2B ZLABZai Lab63.9% -$0.40 $780.7M -
What do Analysts Say About RDY or ZLAB?
Dr Reddy's Laboratories has a consensus price target of --, signalling downside risk potential of -1.96%. On the other hand Zai Lab has an analysts' consensus of -- which suggests that it could grow by 115.61%. Given that Zai Lab has higher upside potential than Dr Reddy's Laboratories, analysts believe Zai Lab is more attractive than Dr Reddy's Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings RDYDr Reddy's Laboratories0 0 0 ZLABZai Lab8 0 0 -
Is RDY or ZLAB More Risky?
Dr Reddy's Laboratories has a beta of 0.508, which suggesting that the stock is 49.207% less volatile than S&P 500. In comparison Zai Lab has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.26999999999999%.
-
Which is a Better Dividend Stock RDY or ZLAB?
Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.6%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.94% of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or ZLAB?
Dr Reddy's Laboratories quarterly revenues are $956.9M, which are larger than Zai Lab quarterly revenues of $102.3M. Dr Reddy's Laboratories's net income of $149.8M is higher than Zai Lab's net income of -$41.7M. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 33.88x while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.76x versus 6.66x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr Reddy's Laboratories3.76x 33.88x $956.9M $149.8M ZLABZai Lab6.66x -- $102.3M -$41.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
